{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:18:24Z","timestamp":1788679104175,"version":"build-2803163510"},"reference-count":120,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clinthera.2023.01.006","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T04:26:56Z","timestamp":1675312016000},"page":"177-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Comorbidities in Psoriatic Arthritis: A Narrative Review"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-9394","authenticated-orcid":false,"given":"Alexandros","family":"Panagiotopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"238","key":"10.1016\/j.clinthera.2023.01.006_bib0001","first-page":"127","article-title":"Psoriatic arthritis (PSA)\u2014an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"QJM An Int J Med"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0003","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/rheumatology\/kes324","article-title":"Prevalence and treatment patterns of psoriatic arthritis in the UK","volume":"52","author":"Ogdie","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0005","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/ard.2008.094839","article-title":"Cardiovascular morbidity in psoriatic arthritis","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0006","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s10067-019-04528-y","article-title":"Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study","volume":"38","author":"Kibari","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0007","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X21998279","article-title":"Psoriatic arthritis and the association with cardiometabolic disease: a narrative review","volume":"13","author":"Karmacharya","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0009","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjd.12473","article-title":"Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"169","author":"Coto-Segura","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3899\/jrheum.160861","article-title":"The risk of developing diabetes mellitus in patients with psoriatic arthritis: a cohort study","volume":"44","author":"Eder","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0011","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40744-020-00206-7","article-title":"Psoriatic arthritis and diabetes mellitus: a narrative review","volume":"7","author":"Dal Bello","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0012","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/acr.20363","article-title":"Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0013","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.semarthrit.2020.02.001","article-title":"Epidemiology of depression and anxiety in patients with psoriatic arthritis: a systematic review and meta-analysis","volume":"50","author":"Zusman","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0014","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/1756-185X.13553","article-title":"Systematic review of depression and anxiety in psoriatic arthritis","volume":"22","author":"Kamalaraj","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1203475420977477","article-title":"Risk of depression in patients with psoriatic disease: a systematic review and meta-analysis","volume":"25","author":"Lukmanji","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0016","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/7854_2012_211","article-title":"Inflammation and depression","volume":"14","author":"Zunszain","year":"2013","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10067-019-04734-8","article-title":"Systematic review of mental health comorbidities in psoriatic arthritis","volume":"39","author":"Zhao","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0018","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ncprheum0670","article-title":"Psoriatic disease\u2014from skin to bone","volume":"3","author":"Ritchlin","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0019","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.31138\/mjr.33.1.150","article-title":"Choosing the appropriate target for the treatment of psoriatic arthritis: TNFa, IL-17, IL-23 or JAK Inhibitors?","volume":"33","author":"Gialouri","year":"2022","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.det.2014.09.003","article-title":"Psoriasis and the life cycle of persistent life effects","volume":"33","author":"Garshick","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0022","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3899\/jrheum.210349","article-title":"Does age matter in psoriatic arthritis? A narrative review","volume":"49","author":"Fragoulis","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.01668","article-title":"Psoriasis, cardiovascular events, and biologics: lights and shadows","volume":"9","author":"Caiazzo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0024","first-page":"23","article-title":"Psoriasis and cardiovascular disease: novel mechanisms and evolving therapeutics","author":"Weber","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0025","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.mcna.2015.08.001","article-title":"Psoriasis and cardiovascular disease","volume":"99","author":"Shahwan","year":"2015","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0026","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/08830185.2018.1539084","article-title":"Psoriasis and cardiovascular disease: the elusive link","volume":"38","author":"Manolis","year":"2019","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0027","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s12325-020-01346-6","article-title":"Psoriasis and cardiovascular risk: a comprehensive review","volume":"37","author":"Masson","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0028","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0029","first-page":"61","article-title":"Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data","author":"Contessa","year":"2011","journal-title":"Reumatismo"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/ATVBAHA.110.214585","article-title":"Carotid intima-media thickness in psoriatic arthritis","volume":"31","author":"Di Minno","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0031","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/rheumatology\/kes213","article-title":"Increase in ventricular-arterial stiffness in patients with psoriatic arthritis","volume":"51","author":"Shang","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0032","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/ard.2008.094151","article-title":"Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARR\u00c9 Investigation","volume":"68","author":"van Halm","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0033","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ard.2010.143396","article-title":"The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study","volume":"70","author":"Lindhardsen","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7659","key":"10.1016\/j.clinthera.2023.01.006_bib0034","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0035","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/ard.2009.122226","article-title":"Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity","volume":"69","author":"Solomon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0036","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/kes243","article-title":"Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis","volume":"52","author":"Liao","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0037","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0038","article-title":"Inflammation as a cardiovascular risk factor","volume":"109","author":"Willerson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0039","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0040","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","article-title":"Cardiovascular risk profile of patients with psoriatic arthritis compared to controls\u2014the role of inflammation","volume":"47","author":"Tam","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0041","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2011-200567","article-title":"Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence","volume":"71","author":"Johnsson","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0042","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.semarthrit.2006.09.001","article-title":"Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis","volume":"36","author":"Kimhi","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0043","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1056\/NEJM199910073411501","article-title":"Body-mass index and mortality in a prospective cohort of U.S. adults","volume":"341","author":"Calle","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0044","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.ATV.19.4.972","article-title":"C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction","volume":"19","author":"Yudkin","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1043-2760(00)00301-5","article-title":"Adipose tissue as an endocrine organ","volume":"11","author":"Ahima","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0046","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/annrheumdis-2011-201273","article-title":"Obesity and risk of incident psoriatic arthritis in US women","volume":"71","author":"Li","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0047","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.01.006_bib0048","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1529-8019.2009.01281.x","article-title":"Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy","volume":"23","author":"Bardazzi","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0049","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"Di Minno","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0051","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1177\/039463201002300334","article-title":"Sudden progression from impaired glucose tolerance to type 2 diabetes after discontinuation of administration of anti-tumor necrosis factor-alpha antibody infliximab","volume":"23","author":"Ursini","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0052","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/157016110791112269","article-title":"Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors","volume":"8","author":"E Toms","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0053","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/ard.59.11.904","article-title":"Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease","volume":"59","author":"Jones","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0054","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-017-1439-1","article-title":"Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis","volume":"19","author":"Deyab","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0055","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10067-013-2369-1","article-title":"Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients","volume":"33","author":"Costa","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0056","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jbspin.2019.12.004","article-title":"Cardiovascular risk in psoriatic arthritis, a narrative review","volume":"87","author":"Verhoeven","year":"2020","journal-title":"Jt Bone Spine"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2023.01.006_bib0057","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11739-011-0704-6","article-title":"TNF-\u03b1 blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis","volume":"7","author":"Di Minno","year":"2012","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0058","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/1574887113666180314105511","article-title":"Cardiovascular risk markers and major adverse cardiovascular events in psoriatic arthritis patients","volume":"13","author":"Peluso","year":"2018","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0059","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0060","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0061","first-page":"100","article-title":"Effects of interleukin 17a inhibition on myocardial deformation and vascular function in psoriasis","volume":"36","author":"Makavos","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0062","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0063","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1468-3083.2012.04500.x","article-title":"Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12\/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"27","author":"Tzellos","year":"2013","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0064","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0065","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0066","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2020.2977","article-title":"Association between early severe cardiovascular events and the initiation of treatment with the anti\u2013interleukin 12\/23p40 antibody ustekinumab","volume":"156","author":"Poizeau","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0067","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","article-title":"The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids","volume":"60","author":"Persson","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.01.006_bib0068","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2022-eular.1762","article-title":"OP0027. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0069","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jid.2018.09.021","article-title":"Antagonization of IL-17a attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis","volume":"139","author":"Sch\u00fcler","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0070","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/rheumatology\/keab655","article-title":"Cardiovascular disease in psoriatic arthritis: facts and unmet needs","volume":"61","author":"Gialouri","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0071","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0072","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis funding sources","volume":"43","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0073","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1080\/14712598.2022.2093106","article-title":"Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome","volume":"22","author":"Trovato","year":"2022","journal-title":"Exp Opin Biol Ther"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0074","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.immuni.2018.09.011","article-title":"An interleukin-23-interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis","volume":"49","author":"Fatkhullina","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0075","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/keab474","article-title":"Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease\u2014results of the Immune Metabolic Associations in Psoriatic Arthritis study","volume":"61","author":"Ferguson","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0076","unstructured":"Risk Factors for Major Adverse Cardiovascular Events in Patients Aged \u2265 50 Years with RA and \u2265 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b\/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors [ACR Meeting Abstracts website]. Available at: https:\/\/acrabstracts.org\/abstract\/risk-factors-for-major-adverse-cardiovascular-events-in-patients-aged-\u2265-50-years-with-ra-and-\u2265-1-additional-cardiovascular-risk-factor-results-from-a-phase-3b-4-randomized-safety-stud. Accessed September 7, 2022."},{"key":"10.1016\/j.clinthera.2023.01.006_bib0077","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20976975","article-title":"Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus","volume":"12","author":"Fragoulis","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0078","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jdv.14175","article-title":"The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis","volume":"31","author":"Wu","year":"2017","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-11-200","article-title":"So depression is an inflammatory disease, but where does the inflammation come from?","volume":"11","author":"Berk","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0080","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-pharmtox-010617-052823","article-title":"Inflammatory mediators in mood disorders: therapeutic opportunities","volume":"58","author":"Pfau","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0081","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/npp.2016.90","article-title":"Immune and neuroendocrine mechanisms of stress vulnerability and resilience","volume":"42","author":"M\u00e9nard","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0082","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/nn.4113","article-title":"Neuroimmune mechanisms of depression","volume":"18","author":"Hodes","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0083","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.autrev.2018.11.007","article-title":"Amplifying the concept of psoriatic arthritis: the role of autoimmunity in systemic psoriatic disease","volume":"18","author":"Chimenti","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0084","doi-asserted-by":"crossref","first-page":"e24833","DOI":"10.1097\/MD.0000000000024833","article-title":"Mild cognitive impairment in psoriatic arthritis","volume":"100","author":"Di Carlo","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0085","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jpsychores.2012.08.008","article-title":"Alexithymia and emotional awareness in females with Painful Rheumatic Conditions","volume":"73","author":"Baeza-Velasco","year":"2012","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0086","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3389\/fimmu.2019.01696","article-title":"The role of inflammation in depression and fatigue","volume":"10","author":"Lee","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0087","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/ard.2009.107912","article-title":"Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study","volume":"69","author":"Cavanagh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0088","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S2215-0366(18)30255-4","article-title":"Rheumatoid arthritis and depression: an inflammatory perspective","volume":"6","author":"Nerurkar","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0089","first-page":"1","article-title":"Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients","volume":"3","author":"Tabra","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0090","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4306\/pi.2013.10.3.294","article-title":"Plasma levels of IL-23 and IL-17 before and after antidepressant treatment in patients with major depressive disorder","volume":"10","author":"Kim","year":"2013","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0091","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/jpm11030220","article-title":"Expansion of CD4 T lymphocytes expressing interleukin 17 and tumor necrosis factor in patients with major depressive disorder","volume":"11","author":"Alvarez-Mon","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0092","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/jpm11020066","article-title":"Inflammatory versus anti-inflammatory profiles in major depressive disorders\u2014the role of IL-17, IL-21, IL-23, IL-35 and Foxp3","volume":"11","author":"Ga\u0142ecka","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0093","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001376","article-title":"Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features","volume":"6","author":"Fragoulis","year":"2020","journal-title":"RMD Open."},{"key":"10.1016\/j.clinthera.2023.01.006_bib0094","doi-asserted-by":"crossref","unstructured":"Gialouri C, Evangelatos G, Zhao SS, et\u00a0al. Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients' perception?Clin Exp Rheumatol. [Epub ahead of print 2022 Jul 8]. doi:10.55563\/clinexprheumatol\/8qxo80","DOI":"10.55563\/clinexprheumatol\/8qxo80"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.imlet.2007.08.009","article-title":"Immune regulation in psoriasis and psoriatic arthritis\u2014recent developments","volume":"114","author":"Hueber","year":"2007","journal-title":"Immunol Lett"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0096","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0097","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058497","article-title":"Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis","volume":"12","author":"Lu","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0098","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-4362.1993.tb05031.x","article-title":"Psychosocial consequences of rejection and stigma feelings in psoriasis patients","volume":"32","author":"Ginsburg","year":"1993","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0099","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2133.2002.04899.x","article-title":"Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients","volume":"147","author":"Vardy","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2019.06.005","article-title":"The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis","volume":"33","author":"Zhao","year":"2019","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0101","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40744-020-00202-x","article-title":"The impact of comorbidity on patient-reported outcomes in psoriatic arthritis: a systematic literature review","volume":"7","author":"Ca\u00f1ete","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0102","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","article-title":"Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment","volume":"29","author":"Mease","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med (Northfield Il)"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0104","first-page":"250","volume":"150","author":"Perrot","year":"2010","journal-title":"Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST)"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105420","article-title":"Tender to touch\u2014prevalence and impact of concomitant fibromyalgia and enthesitis in spondyloarthritis: an ancillary analysis of the ASAS PerSpA study","volume":"89","author":"Fitzgerald","year":"2022","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0106","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","article-title":"Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study","volume":"76","author":"Michelsen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0107","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/acr.21725","article-title":"Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life","volume":"64","author":"Kotsis","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0108","first-page":"06","article-title":"Rasch analysis of the hospital anxiety and depression scale in psoriatic arthritis: results from the PRESTA study [abstract]","author":"Ndosi","year":"2015","journal-title":"White Rose University Consortium"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0109","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","article-title":"Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety","volume":"34","author":"Lemos","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0110","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.1993","article-title":"Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials","volume":"102","author":"Reich","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0111","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2009.09.014","article-title":"Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"63","author":"Langley","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0112","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/09546634.2018.1466021","article-title":"Improvement of depressive symptoms in patients with moderate to severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton Depression Rating Scale measures and 18 fluorodeoxyglucose (FDG) positron em","volume":"29","author":"Kim","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0113","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11156","article-title":"Long-term safety and tolerability of apremilast versus placebo in psoriatic arthritis: a pooled safety analysis of three phase III, randomized, controlled trials","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0114","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/jdv.16231","article-title":"The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database","volume":"34","author":"Vasilakis-Scaramozza","year":"2020","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","article-title":"Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0116","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/jdv.12909","article-title":"Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review","volume":"29","author":"Fleming","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0117","first-page":"495","article-title":"Apremilast (Otezla): A new oral treatment for adults with psoriasis and psoriatic arthritis","volume":"40","author":"Zerilli","year":"2015","journal-title":"Pharm Ther"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0119","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.006_bib0120","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2014-206807","article-title":"EULAR recommendations for patient education for people with inflammatory arthritis","volume":"74","author":"Zangi","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:58:58Z","timestamp":1758963538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0149291823000267"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidities in Psoriatic Arthritis: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}